New drugs in systemic lupus erythematosus: When to start and when to stop

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.78, 2013, Pages

  Mosca, Marta ^a   van Vollenhoven, Ronald ^b  

^a UNIVERSITY OF PISA   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Belimumab; Clinical practice; Rituximab

Indexed keywords

ANTIMALARIAL AGENT; BELIMUMAB; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; RITUXIMAB;

ARTICLE; DISEASE ACTIVITY; DRUG INDICATION; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885695945     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. MAK A, CHEUNG MWL, CHIEW HJ, LIU Y, HO RC: Global Trend of Survival and Damage of Systemic Lupus Erythematosus: Meta-Analysis and Meta-Regression of Observational Studies from the 1950s to 2000s. Semin Arthritis Rheum 2012; 41: 830-9.
2. UROWITZ MB, GLADMAN DD, TOM BDM, IBANEZ D, FAREWELL VT: Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008; 35: 2152-8.
3. DORIA A, IACCARINO L, GHIRARDELLO A et al.: Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006; 119: 700-6.
4. NOSSENT J, CIKES N, KISS E et al.: Current causes of death in systemic lupus erythematosus in Europe, 2000--2004: relation to disease activity and damage accrual. Lupus 2007; 16: 309-17.
5. URAMOTO KM, MICHET CJ, THUMBOO J, SUNKU J, O'FALLON MW, GABRIEL SE: Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999; 42: 46-50.
6. FANGTHAM M, PETRI M: 2013 Update: Hopkins Lupus Cohort. Curr Rheumatol Rep 2013; 15: 360.
7. MOSCA M, BOUMPAS DT, BRUCE IN et al.: Treat-to-target in systemic lupus erythematosus: where are we today?. Clin Exp Rheumatol 2012; 30 (Suppl. 73): S112-15.
8. NOSSENT J, KISS E, ROZMAN B et al.: Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010; 19: 949-56.
9. ZEN M, NALOTTO L, CANOVA M et al.: Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol 2012; 30: 856-63.
10. BARR SG, ZONANA-NACACH A, MAGDER LS, PETRI M: Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2682-8.
11. LAUSTRUP H, VOSS A, GREEN A, JUNKER P: SLE disease patterns in a Danish populationbased lupus cohort: an 8-year prospective study. Lupus 2010; 19, 239-46.
12. NIKPOUR M, UROWITZ MB, IBANEZ D, GLADMAN DD: Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009; 61, 1152-8.
13. UROWITZ MB, FELETAR M, BRUCE IN, IBANEZ D, GLADMAN DD: Prolonged remission in systemic lupus erythematosus. J Rheumato 2005; l32, 1467-72.
14. UROWITZ MB, GLADMAN DD, IBANEZ D et al.: Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res 2012; 64: 132-7.
15. WARD MM: Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol 2009; 36: 63-7.
16. MORONI G, GALLELLI B, QUAGLINI S et al.: Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 2006; 21: 1541-8.
17. Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus: Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: Report of a consensus meeting. Arthritis Rheum 2004; 50: 3427-31.
18. MOSCA M, TANI C, CARLI L, BOMBARDIERI S: Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S126-9.
19. LOONEY RJ, ANOLIK JH, CAMPBELL D et al.: B Cell Depletion as a Novel Treatment for Systemic Lupus Erythematosus. A Phase I/II Dose-Escalation Trial of Rituximab. Arthritis Rheum 2004; 50: 2580-9.
20. LEANDRO MJ, CAMBRIDGE G, EDWARDS JC, EHRENSTEIN MR, ISENBERG DA: B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005; 44: 1542-5.
21. NG KP, LEANDRO MJ, EDWARDS JC, EHRENSTEIN MR, CAMBRIDGE G, ISENBERG DA: Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006; 65: 942-5.
22. NG KP, CAMBRIDGE G, LEANDRO MJ, EDWARDS JCW, EHRENSTEIN M, ISENBERG DA: B cell depletion therapy in systemic lupus erythematosus: longterm follow-up and predictors of response. Ann Rheum Dis 2007; 66: 1259-62.
23. T JONSDOTTIR, I GUNNARSSON, A RISSELADA, E W HENRIKSSON, L KLARESKOG, R F van VOLLENHOVEN: Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008; 67: 330-4.
24. ALBERT D, DUNHAM J, KHAN S et al.: Variability in the biological response to anti-CD20 B-cell depletion in SLE. Ann Rheum Dis 2008; 67: 1724-31.
25. GUNNARSSON I, SUNDELIN B, JONSDOTTIR T, JACOBSON SH, HENRIKSSON EW, van VOLLENHOVEN RF: Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56: 1263-72.
26. RAMOS-CASALS M, SOTO MJ, CUADRDAO MA, KHAMASHTA MA: Rituximab in systemic lupus erythematosus. A systematic review of off-label use in 188 cases. Lupus 2009; 18: 767-76.
27. MURRAY E, PERRY M: Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 201; 29: 707-16.
28. GüRCAN HM, KESKIN DB, STERN JNH, NITZBERG MA, SHEKHANI H, AHMED AR: A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009; 9: 10-25.
29. MERRILL JT, NEUWELT MC, WALLACE DJ et al.: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial. Arthritis Rheum 2010; 62: 222-33.
30. REDDY V, JAYNE D, CLOSE D, ISENBERG D: B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 2013, 15 (Suppl. 1): S2.
31. van VOLLENHOVEN R, SEDDIGHZADEH M, JACOBSEN S et al.: An estimate of the proportion of patients with SLE receiving off-label treatment with rituximab in European countries Ann Rheum Dis 2012; 71 (Suppl. 3): 539.
32. van VOLLENHOVEN R, MILD M, DORNER T et al.: Off-label use of rituximab for SLE in Europe: a comparison to patients treated with conventional immunosuppressive medica tions. Ann Rheum Dis 201 3; 72 (Suppl. 3): 254.
33. CONDON MB, ASHBY D, PEPPER RJ et al.: Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013; 72: 1280-6.
34. LOONEY RJ: B cell targeted therapies for systemic lupus erythematosus. An update on clinical trial data. Drugs 2010; 70: 529-40.
35. NAVARRA SV, GUZMAN RM, GALLACHER AE et al.: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-31.
36. DING HJ, GORDON C: New biologic therapy for systemic lupus erythematosus. Curr Opin Pharmacol 2013; 13: 405-12.
37. Van VOLLENHOVEN RF, PETRI MA, CERVERA R et al.: Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012; 71: 1343-9.
38. MANZI S, SANCHEZ-GUERRERO J, MERRILL JT et al.: Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012; 71: 1833-8.
39. CALVO-ALEN J, SILVA-FERNANDEZ L, UCARANGULO E et al.: SER consensus statement on the use of biologic therapy for systemic lupus erythematosus. Reumatol Clin 2013; 9: 281-96.
40. RAMOS-CASALS M, RUIZ-IRASTORZA G, JIMENEZ-ALONSO J, KHAMASHTA MA: Belimumab in systemic lupus erythematosus: a guide for its use in the daily practice. Rev Clin Esp 2013; 213: 66-7.
41. PARODIS I, AXELSSON M, GUNNARSON I: Belimumab in systemic lupus erythematosus: a practice-based view. Lupus 2013; 22: 372-80.
42. FURST DE, KEYSTONE EC, SO AK et al.: Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013; 72 (Suppl. 2); ii 2-34
43. ARINGER M, BURKHARDT H, BURMESTER GR et al.: Current evidence on "off-label" therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents in Germany, Austria and Switzerland-a consensus report. Lupus 2012; 21: 386-401.
44. DÖRNER T, KAUFMANN J, WEGENER WA, TEOH N, GOLDENBERG DM, BURMESTER GR: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8; R74.
45. DING HJ, GORDON: New biologic therapy for systemic lupus erythematosus. Curr Opin Pharmacol 2013; 13: 1-8.